Navigation Links
New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
Date:10/29/2008

One in five women suffer from fibroid symptoms at least 5 years before seeking treatment.

LAS VEGAS, Oct. 29 /PRNewswire/ -- At the annual meeting of the American Association of Gynecologic Laparoscopists (AAGL), ETHICON Women's Health & Urology today announced results of a seven-country study measuring the effects of uterine fibroids and associated symptoms on quality of life (QoL). Researchers found that one in five women suffer with symptomatic fibroids for more than 5 years before getting medical treatment. Further, despite diagnosis, more than one-third of women remain untreated -- either surgically or medically -- for their fibroids, which means that many women continue to experience symptoms severe enough to affect QoL.

Uterine fibroids are benign tumors made up of fibrous and muscular tissue in the uterine wall. They occur in one third of women over age thirty and are a major reason for hysterectomy worldwide. Women who have uterine fibroids may experience debilitating symptoms such as abnormal bleeding, pain, pressure in the pelvic region, painful intercourse, frequent urination or infertility.

The CHASM (Cross-Sectional Survey of HRQoL And Symptoms of Myoma) study was sponsored by ETHICON and designed to quantify the fibroid burden on a woman's QoL and to better understand current management of symptomatic fibroids. More than 2,500 adult women experiencing fibroid symptoms with a self-reported physician diagnosis or previous treatment for uterine fibroids were surveyed in the United States, Canada and five European countries. Researchers found that:

-- Overall, 22% of women who have been diagnosed with uterine fibroids

waited at least five years before getting treatment.

-- A substantial percentage of women (almost 45% of those diagnosed and

almost 70% of those with symptoms) have not sought any treatment in the

past year

-- Of those who have sought medical care and been diagnosed, more than 36%

have not received surgical or medical treatment, despite reporting

symptoms that interfere with their quality of life

-- Women who have opted for surgical treatment report a better quality of

life outcome than those who have used medication

ETHICON Women's Health & Urology currently is recruiting for two clinical trials to evaluate the safety and effectiveness of Doppler guided Uterine Artery Occlusion (D-UAO) as treatment for the reduction of fibroid-associated bleeding (in the US) and as a treatment for the reduction of fibroid-associated symptoms (in the EU). Details about both studies can be found at: http://www.clinicaltrials.gov, keyword "doppler guided uterine artery occlusion".

Results of the CHASM study will be presented on October 30, 2008 as part of Plenary Session 7, Management of Myomas, at AAGL's annual meeting. Details about the session can be found at http://www.aagl.org/annual-meeting.

About Ethicon Women's Health and Urology

ETHICON Women's Health & Urology offers treatment solutions for a range of common, female pelvic health disorders. The technologies are marketed under the GYNECARE family of brands and include treatments for menorrhagia (heavy periods), fibroids, stress urinary incontinence and pelvic organ prolapse. ETHICON Women's Health & Urology is a division of ETHICON, Inc, a Johnson & Johnson company. For more information visit http://www.gynecare.com.


'/>"/>
SOURCE ETHICON Women?s Health & Urology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Extremity Braces & Support) is Expected to Gain a Significant ... Prone to Orthopedic Ailments  ... , , According ... Market Study on Medical Implants Sterile Packaging: Clamshell Product Type ...
(Date:12/2/2016)... 2016   CytoSorbents Corporation (NASDAQ: CTSO ... Union approved CytoSorb ® cytokine adsorber to treat ... announced that Dr. Phillip Chan , Chief Executive ... Micro Main Event investor conference held from December ... Sunset Boulevard Hotel in Los Angeles, California ...
(Date:12/2/2016)... , December 2, 2016 On Thursday, ... 1.36%; the Dow Jones Industrial Average edged 0.36% higher, to ... down 0.35%. Losses were broad based as six out of ... initiated research reports on the following Services equities: Myriad Genetics ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/2/2016)... , ... December 02, 2016 , ... "Pro3rd Accents Volume ... editors to create versatile lower third titles with just a few clicks of the ... Volume 2 includes 30 lower third animations. Choose from various styles with accented animations, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a ... applications, was named the best Sales Team of 2016 as part of the ... today by the Software & Information Industry Association (SIIA), the principal trade association ...
(Date:11/30/2016)... Boston, Massachusetts (PRWEB) , ... November 30, 2016 ... ... is proud to announce that we have been designated as a Cigna Infertility ... meet or exceed rigorous performance standards. , “It’s an honor to be ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard ... 75, an annual ranking and recognition of the largest closely held companies headquartered ... ranked from 2008-2016. In addition, Standard Process was awarded the Talent Award for ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... workers have been a focus of public policymakers and system stakeholders in many ... (WCRI) released its Medical Price Index for Workers’ Compensation, Eighth Edition (MPI-WC) ...
Breaking Medicine News(10 mins):